Literature DB >> 24034000

Ethical evaluation of risks related to living donor transplantation programs.

N Panocchia1, M Bossola, P Silvestri, E Midolo, A A Teleman, L Tazza, D Sacchini, R Minacori, M L Di Pietro, A G Spagnolo.   

Abstract

The shortage of available cadaveric organs for transplantation and the growing demand has incresed live donation. To increase the number of transplantations from living donors, programs have been implemented to coordinate donations in direct or indirect form (cross-over, paired, and domino chain). Living donors with complex medical conditions are accepted by several transplantation programs. In this way, the number of transplants from living has exceeded that from cadaver donors in several European countries. No mortality has been reported in the case of lung, pancreas, or intestinal Living donations, but the perioperative complications range from 15% to 30% for pancreas and lung donors. In living kidney donors, the perioperative mortality is 3 per 10,000. Their frequency of end-stage renal disease does not exceed the United States rate for the general population. However, long-term follow-up studies of living donors for kidney transplantations have several limitations. The frequency of complications in live donor liver transplantation is 40%, of these, 48% are possibly life-threatening according to the Clavien classification. Residual disability, liver failure, or death has occurred in 1% of cases. The changes in live donor acceptance criteria raise ethical issues, in particular, the physician's role in evaluating and accepting the risks taken by the living donor. Some workers argue to set aside medical paternalism on behalf of the principle of donor autonomy. In this way the medical rule "primum non nocere" is overcome. Transplantation centers should reason beyond the shortage of organs and think in terms of the care for both donor and recipient.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24034000     DOI: 10.1016/j.transproceed.2013.07.026

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

Review 1.  Lung transplantation: a treatment option in end-stage lung disease.

Authors:  Marc Hartert; Omer Senbaklavacin; Bernhard Gohrbandt; Berthold M Fischer; Roland Buhl; Christian-Friedrich Vahld
Journal:  Dtsch Arztebl Int       Date:  2014-02-14       Impact factor: 5.594

2.  Liver Living Donation for Cancer Patients: Benefits, Risks, Justification.

Authors:  Silvio Nadalin; Lara Genedy; Alfred Königsrainer
Journal:  Recent Results Cancer Res       Date:  2021

Review 3.  Ethical dilemmas related to living donor liver transplantation in Asia.

Authors:  Lubna Shazi; Zaigham Abbas
Journal:  Ir J Med Sci       Date:  2019-02-23       Impact factor: 1.568

4.  Risk Assessment and Management for Potential Living Kidney Donors: The Role of "Third-Party" Commission.

Authors:  Lucia Tattoli; Davide Santovito; Ida Marina Raciti; Antonio Scarmozzino; Giancarlo Di Vella
Journal:  Front Public Health       Date:  2022-03-17

Review 5.  Should living donor liver transplantation be an option when deceased donation is not?

Authors:  Sarah R Lieber; Thomas D Schiano; Rosamond Rhodes
Journal:  J Hepatol       Date:  2017-11-01       Impact factor: 30.083

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.